APTO:NSD-Aptose Biosciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.28

Change

0.00 (0.00)%

Market Cap

USD 0.20B

Volume

0.71M

Avg Analyst Target

USD 10.50 (+360.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aptose Biosciences Inc (APTO) Stock Analysis:
Based on the Aptose Biosciences Inc stock forecasts from 2 analysts, the average analyst target price for Aptose Biosciences Inc is USD 10.50 over the next 12 months. Aptose Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aptose Biosciences Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Aptose Biosciences Inc’s stock price was USD 2.28. Aptose Biosciences Inc’s stock price has changed by -0.23 % over the past week, +0.12 % over the past month and -63.69 % over the last year.

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients wi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-11-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD133.65B 19.75 16.11
BNTX BioNTech SE

N/A

USD84.40B 11.02 6.84
REGN Regeneron Pharmaceuticals Inc

N/A

USD69.19B 10.29 7.95
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD46.68B 22.02 14.13
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD32.98B N/A N/A
SGEN Seagen Inc

N/A

USD30.99B 55.02 44.86
GMAB Genmab A/S

N/A

USD25.66B 59.56 6.36
ALNY Alnylam Pharmaceuticals Inc

N/A

USD22.55B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing APTO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.95% 28% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.95% 28% F 12% F
Trailing 12 Months  
Capital Gain -63.69% 14% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.69% 14% F 6% F
Trailing 5 Years  
Capital Gain 140.00% 74% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.00% 74% C 76% C
Average Annual (5 Year Horizon)  
Capital Gain 66.83% 81% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.83% 81% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 112.80% 23% F 14% F
Risk Adjusted Return 59.25% 86% B 76% C
Market Capitalization 0.20B 41% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.29 65% D 53% F
Price / Cash Flow Ratio -5.98 49% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -51.18% 56% F 27% F
Return on Invested Capital -52.40% 46% F 16% F
Return on Assets -30.04% 39% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.79 86% B 79% C+
Short Percent 1.01% 86% B 73% C
Beta 1.25 50% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector